Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:42:19.258Z.
Calculation as of: 2026-10-06T14:42:19.258Z.
Quote observation: 2026-10-06T14:40:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88e906b5462319013e69f4ee379284aaffb96e00f9acc248208650345dd3e90c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$6.57B
EBITDA Yield
N/A
TTM Avg
1.73%
3Y Avg
1.16%
5Y Avg
1.16%
Market Cap
$6.53B
EBITDA Yield
5.87%
TTM Avg
7.53%
3Y Avg
7.75%
5Y Avg
5.52%
Market Cap
$6.40B
EBITDA Yield
6.59%
TTM Avg
7.99%
3Y Avg
9.42%
5Y Avg
8.85%
Market Cap
$7.29B
EBITDA Yield
45.28%
TTM Avg
34.53%
3Y Avg
34.53%
5Y Avg
15.09%
Market Cap
$5.95B
EBITDA Yield
2.22%
TTM Avg
1.62%
3Y Avg
2.24%
5Y Avg
4.65%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.62B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.67B | 5.97% | 6.41% | 5.49% | 5.42% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.57B | N/A | 1.73% | 1.16% | 1.16% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 5.87% | 7.53% | 7.75% | 5.52% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.40B | 6.59% | 7.99% | 9.42% | 8.85% |
| GRAIL Inc. (GRAL)vs › | $6.06B | N/A | N/A | N/A | N/A |
| Alkermes plc (ALKS)vs › | $6.93B | 2.24% | 5.56% | 8.89% | 6.62% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.29B | 45.28% | 34.53% | 34.53% | 15.09% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 2.22% | 1.62% | 2.24% | 4.65% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.84B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
